featured
Abemaciclib Plus Pembrolizumab for HR+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
NPJ Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study
NPJ Breast Cancer 2022 Nov 05;8(1)118, HS Rugo, P Kabos, JT Beck, G Jerusalem, H Wildiers, E Sevillano, L Paz-Ares, MJ Chisamore, SC Chapman, AM Hossain, Y Chen, SM TolaneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.